Management and monitoring of cancer-associated retinopathy
| Autor: | Alan M. Roth, John L. Keltner, Charles E. Thirkill, Nancy K. Tyler |
|---|---|
| Rok vydání: | 1992 |
| Předmět: |
Male
Lung Neoplasms Paraneoplastic Syndromes Lipoproteins Blotting Western Enzyme-Linked Immunosorbent Assay Nerve Tissue Proteins Autoimmune retinopathy chemistry.chemical_compound Antigen Retinal Diseases Prednisone Antigens Neoplasm Hippocalcin medicine Biomarkers Tumor Recoverin Humans Carcinoma Small Cell Eye Proteins Aged Monitoring Physiologic Retina business.industry Brain Neoplasms Calcium-Binding Proteins Antibody titer Retinal medicine.disease Ophthalmology medicine.anatomical_structure chemistry Immunology Prednisolone Visual Fields business Retinopathy medicine.drug Follow-Up Studies |
| Zdroj: | Archives of ophthalmology (Chicago, Ill. : 1960). 110(1) |
| ISSN: | 0003-9950 |
| Popis: | • Cancer-associated retinopathy is a rare paraneoplastic event that can involve allergic reactions and result in retinal degradation. A patient, who had a 35-year smoking history, complained of visual loss and was found to have serum antibodies that reacted with an extract of retina, including the previously described retinal cancer-associated retinopathy antigen. Prednisone treatment appeared to reduce the patient's antibody titers to normal levels. Visual fields stabilized, and the patient was able to maintain useful vision throughout the course of treatment until his death 1 year following initial diagnosis. To our knowledge, this is the first reported case in which monitoring of antibody responses to retinal antigens appeared to be useful in the decision whether to initiate prednisone therapy. Rising antibody titers to the cancer-associated retinopathy antigen probably occurs before progressive visual field loss and may be considered an indication for prompt steroid therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|